The FDAs Stance and Why It Misses the Mark In 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance , meaning it raises significant safety concerns. The agency specifically cited risks of immunogenicity , peptide-related impurities , and lack of sufficient safety data for human use
Impurities that rarely matter in adult regenerative protocols but introduce additional variables when fetal development is at stake
adults, members of our team make a point of lifting weights at least 2-3 times per week.1 Strength training outcomes are incremental, so we keep an eye out for any products or therapies that can push us forward along the way
NewBioRx produces BPC-157 using controlled solid-phase peptide synthesis (SPPS), followed by purification through high-performance liquid chromatography (HPLC) to remove truncated peptide fragments and synthesis byproducts
If levels climb high into normal range and symptoms resolve, continue the current protocol
If it seems thicker, more viscous, or if you notice any gel-like consistency when drawing with a syringe, the formulation has likely degraded
